Pulmonary Arterial Hypertension
The 6-minute walk test had prognostic value with respect to mortality in a population of patients with pulmonary arterial hypertension.
Brain natriuretic peptide levels may accurately predict 5-year survival rates in patients with pulmonary arterial hypertension.
The REVEAL risk score gives significant predictive value for long-term survival and changes in mortality risk in patients with PAH.
A fully implantable programmable intravascular delivery system using treprostinil was found to be highly stable in patients with PAH.
A study evaluated whether changes in estimated glomerular filtration rate were predictive of mortality in patients with pulmonary arterial hypertension.
A 40-year-old woman presents with worsening shortness of breath after being treated with long-acting nifedipine for 2 years.
Hemodynamics may improve in patients with chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty with complication rates comparable to pulmonary endarterectomy.
Using biomarkers in pulmonary arterial hypertension may be a less invasive strategy for assessing response to treatment.
Pulmonary arterial hypertension is becoming a major cause of death in patients with systemic sclerosis.
Results show statistically significant differences between SSc-PAH groups and iPAH groups for variables including age, sex, FVC capacity, total lung capacity, and FEV1, among others.
Patients with pulmonary arterial hypertension have reduced cerebrovascular reactivity to CO2.
Borderline PH was linked to increased mortality after adjustment for 34 variables.
Results indicate that further study of the relationship between the 6-minute walk distance test and functional capacity in PAH is necessary.
A study sought to describe the occurrence of different types of pulmonary hypertension in hereditary hemorrhagic telangiectasia.
Depression, anxiety, and reduced healthcare-related quality of life are common in patients with either pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.
A 65-year-old man with COPD presents with worsening exertional dyspnea.
Methamphetamine-associated pulmonary arterial hypertension has a higher risk for clinical worsening compared with idiopathic pulmonary arterial hypertension.
Having at least 2 features of pulmonary veno-occlusive disease demonstrated a trend toward worse survival in patients with pulmonary arterial hypertension and systemic sclerosis.
Pulmonary arterial hypertension tends to vary in presentation in patients of different races and ethnicities.
Differences in right ventricular morphology may predict the hemodynamic nature of pulmonary hypertension.
Pulmonary endarterectomy is an effective and durable treatment for chronic thromboembolic pulmonary hypertension.
Prenatal factors such as intrauterine growth retardation, infection, and placental inflammation can affect lung development in neonates.
The first FDA-approved drug for pediatric pulmonary arterial hypertension will be available in 32 mg tablets for oral suspension.
Researchers were able to successfully use a fully implantable delivery system for treprostinil for adult patients with pulmonary arterial hypertension.
New criteria by the American College of Radiology detail appropriateness of various imaging techniques for suspected pulmonary hypertension.
Computed tomography-derived pulmonary artery-to-aorta ratio can predict pulmonary artery pressure and survival in patients with idiopathic pulmonary fibrosis.
Meta-analysis supports anti-RNP and anti-Sm antibodies as serological biomarkers of PAH risk in patients with SLE.
MRI measures can predict outcomes in pulmonary arterial hypertension.
Pulmonary and genetics experts James E. Loyd, MD, and Wendy Chung, MD, PhD, offer insight into the role of genetics in pulmonary arterial hypertension.
Combination therapy with ambrisentan and tadalafil may improve response in patients with connective tissue disease-associated pulmonary arterial hypertension.